New Haven’s Biohaven Pharmaceutical Holding Co. Ltd. is partnering with an Alzheimer’s disease research consortium on a clinical trial of an investigational drug.
Biohaven is developing the investigational drug trigriluzole, which is intended to control glutamate dysfunction, which studies have shown plays a role in Alzheimer’s disease.
As part of the study collaboration with Alzheimer’s Disease Cooperative Study, Biohaven will fund a phase 2 clinical trial to evaluate the efficacy and safety of using trigriluzole in patients with mild-to-moderate Alzheimer’s.
